Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 244Lung Neoplasms 77Melanoma 57Carcinoma, Renal Cell 44Small Cell Lung Carcinoma 33Colorectal Neoplasms 28Squamous Cell Carcinoma of Head and Neck 24Carcinoma, Transitional Cell 24Neoplasms 23Triple Negative Breast Neoplasms 22Neoplasm Metastasis 21Carcinoma, Hepatocellular 19Ovarian Neoplasms 17Mesothelioma 17Pancreatic Neoplasms 15Mesothelioma, Malignant 15Stomach Neoplasms 13Breast Neoplasms 13Uterine Cervical Neoplasms 12Urinary Bladder Neoplasms 10Head and Neck Neoplasms 10Carcinoma, Merkel Cell 10Kidney Neoplasms 9Adenocarcinoma of Lung 8Esophageal Neoplasms 7Endometrial Neoplasms 7Lymphoma 6Carcinoma, Squamous Cell 6Brain Neoplasms 6Prostatic Neoplasms 5

Interventions

Nivolumab 2Docetaxel 2spartalizumab 1sintilimab 1Carboplatin 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Squamous Cell Non-small Cell Lung Cancer × Nivolumab × Thoracic × Clear all
NCT01642004 2022-12-28

Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)

Bristol-Myers Squibb

Phase 3 Completed
272 enrolled 23 charts
Thoracic

Squamous Cell Non-small Cell Lung Cancer

NCT01721759 2022-06-28

Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens

Bristol-Myers Squibb

Phase 2 Completed
117 enrolled 17 charts
Thoracic

Squamous Cell Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡